

# 2026 Health Plan Coding Guide



Trinity Health Plan  
of Michigan

---

We understand the challenges of working with multiple payers and meeting measurements, guidelines and documentation for Medicare beneficiaries. This Coding Guide is intended to make things easier for you and your staff when working with our health plan. The guide includes assistance in understanding:

- Star Ratings and the HEDIS reporting process.
- Your role in reporting and documenting care.
- Medical record requests (MRR).
- Star measure guidance and codes.

We always welcome your feedback on how we can make this guide better.

---

***“Thank you for partnering with our health plan to improve the health and well-being of our members. We sincerely consider you our partner and recognize that we cannot succeed without the compassionate and high-quality care delivered by the providers in our network. Working together, we can have a positive impact on patient outcomes.”***



**Greg Wise, MD, FAAFP,**  
Chief Medical Officer

## Table of Contents

|    |                                                    |
|----|----------------------------------------------------|
| 4  | Star Ratings, HEDIS Reporting<br>and Documentation |
| 9  | Medical Record Collection/<br>Delivery Methods     |
| 13 | HEDIS-Related Star Measures                        |
| 27 | HEDIS-Related Display Measures                     |
| 30 | Contact Us                                         |

# Star Ratings, HEDIS Reporting and Documentation

## What are Star Ratings?

All Medicare Advantage plans are awarded Star ratings annually by the Centers for Medicare & Medicaid Services (CMS). On a scale of one to five, a 5-Star rating is considered excellent. Our health plan's overall Star rating combines rankings of quality and performance, including how well we help our members to stay healthy and manage chronic conditions. This information is gathered from HEDIS® scores, HOS and CAHPS Survey data and CMS administrative data. This guide covers the HEDIS-related Star Measures, and the needed coding and documentation for those measures, used in our HEDIS scores.

## HEDIS Reporting and the Role You Play

HEDIS, the acronym for Healthcare Effectiveness Data and Information Set, is a performance measurement tool for health plans, administered by the National Committee for Quality Assurance (NCQA). HEDIS measures are a significant component of Medicare Star Ratings and the NCQA accreditation process. The coding and documentation necessary to meet measures is collected from our claims database, supplemental data submission feeds, and review of medical records. In the eyes of measurement reporting, if it isn't documented, then it didn't happen. To meet requirements, it's important to make every visit count. Useful tips include:

- Promote all patient's health and encourage an annual wellness visit before June 30 each year, when possible.
- Give patients reminder calls 48 hours before their appointments.
- Schedule follow-up visits before patients leave.
- Accurately code all claims.
- Thoroughly document all care in the patient's chart at the time service is provided, including date and provider's signature.
- Utilize our health plan's Gaps In Care report to close measures and strengthen patient relationships.

## HEDIS Data Collection Methods

The health plan collects HEDIS data to close gaps in care and report HEDIS measures using three primary methods.

1. Claims data is analyzed to identify services provided and any gaps in care based on billing information.
2. Supplemental data feeds may be integrated from sources, such as electronic health records and lab results, to provide additional clinical information not captured in claims. We can work with your office to configure a standard supplemental feed - contact StarsAndHEDIS@mchs.com to get started.

3. Medical record collection and review. Please see the Medical Record Collection/Delivery Methods section of this guide for more information.

**Feel free to request a gaps in care report for your office by emailing [starsandhedis@mchs.com](mailto:starsandhedis@mchs.com)**

### What are CPT Category II codes?

Current Procedural Terminology (CPT) Category II codes were developed by the American Medical Association (AMA) as a supplemental performance tracking set of procedural codes in addition to the Category I and III code settings.

Category I codes are used for tracking and billing common procedures.

- Category III codes are temporary codes for emerging technology.
- Category II codes are optional and intended to be used for measuring performance on quality metrics such as Healthcare Effectiveness Data and Information Set (HEDIS®)

Category II codes are alphanumeric and consist of four digits followed by the letter 'F'.

Category II codes are NOT billing codes; they are used to track services on claims for performance measurement.

Category II codes are not to be used as a substitute for Category I codes.

### What is the purpose of CPT Category II codes?

Category II codes are intended to facilitate the reporting of services or test results that support quality of care performance measures. MediGold highly encourages (and even incentivizes\*) clinical office staff to utilize CPT II codes.

By accurately coding you can decrease the need for manual record abstraction and chart review, minimizing the burden on physicians and office staff to report this information through other methods.

### CPT Category II codes are arranged according to the following categories:

| Category                                  | Code Range    | Category                                       | Code Range    |
|-------------------------------------------|---------------|------------------------------------------------|---------------|
| Composite measures                        | 0001F-0015F   | Therapeutic, preventive or other interventions | 4000F - 4306F |
| Patient management                        | 0500F - 0575F | Follow-up or other outcomes                    | 5005F - 5100F |
| Patient history                           | 1000F - 1220F | Patient safety                                 | 6005F - 6045F |
| Physical examination                      | 2000F - 2050F | Structural measures                            | 7010F - 7025F |
| Diagnostic/screening processes or results | 3006F - 3573F |                                                |               |

CPT II codes allow providers to measure and display the quality of care they provide.

CPT® is a registered trademark of the American Medical Association. Copyright 2016 American Medical Association (AMA). All rights reserved.  
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

|     | MEASURE                                                                                                                | CATEGORY II CPT CODE                                                                                                  | INCENTIVE |
|-----|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------|
| EED | Comprehensive Diabetes Care-Retinal Eye Exam <i>(One time per year.)</i>                                               | <b>2022F</b><br><b>Filed with ICD-10 Diag Codes:</b><br>ICD-10-E10.9, E10.10-E13.9,<br>O24.011-O24.33, O24.811-O24.83 | \$20      |
|     |                                                                                                                        | <b>2023F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$20      |
|     |                                                                                                                        | <b>2024F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$20      |
|     |                                                                                                                        | <b>2025F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$20      |
|     |                                                                                                                        | <b>2026F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$20      |
|     |                                                                                                                        | <b>2033F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$20      |
| GSD | Comprehensive Diabetes Care-HbA1c level less than 7.0 <i>(Diabetic members only.)</i>                                  | <b>3044F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$10      |
|     | Comprehensive Diabetes Care-HbA1c level greater than 9.0 <i>(Diabetic members only.)</i>                               | <b>3046F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$10      |
|     | Comprehensive Diabetes Care-HbA1c level greater than or equal to 7.0 and less than 8.0 <i>(Diabetic members only.)</i> | <b>3051F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$10      |
|     | Comprehensive Diabetes Care-HbA1c level greater than or equal to 8.0 and less than 9.0 <i>(Diabetic members only.)</i> | <b>3052F</b><br><b>Filed with ICD-10 Diag Codes:</b> ICD-10-E10.9,<br>E10.10-E13.9, O24.011-O24.33, O24.811-O24.83    | \$10      |
| CBP | Controlling Blood Pressure- Systolic <i>(Essential Hypertensive members only.)</i>                                     | <b>3074F</b><br><b>Filed with ICD-10 Diag Code:</b> I10                                                               | \$5       |
|     | Controlling Blood Pressure- Systolic <i>(Essential Hypertensive members only.)</i>                                     | <b>3075F</b><br><b>Filed with ICD-10 Diag Code:</b> I10                                                               | \$5       |
|     | Controlling Blood Pressure- Systolic <i>(Essential Hypertensive members only.)</i>                                     | <b>3077F</b><br><b>Filed with ICD-10 Diag Code:</b> I10                                                               | \$5       |
|     | Controlling Blood Pressure- Diastolic <i>(Essential Hypertensive members only.)</i>                                    | <b>3078F</b><br><b>Filed with ICD-10 Diag Code:</b> I10                                                               | \$5       |
|     | Controlling Blood Pressure- Diastolic <i>(Essential Hypertensive members only.)</i>                                    | <b>3079F</b><br><b>Filed with ICD-10 Diag Code:</b> I10                                                               | \$5       |
|     | Controlling Blood Pressure- Diastolic <i>(Essential Hypertensive members only.)</i>                                    | <b>3080F</b><br><b>Filed with ICD-10 Diag Code:</b> I10                                                               | \$5       |
| MRP | Medication Reconciliation Post- Discharge                                                                              | <b>1111F</b>                                                                                                          | \$25      |

\*Please note that the codes listed here, when applied correctly, will result in closure of an identified care opportunity. This is not a guarantee of benefits or payment. Benefits are subject to the terms and limitations of the plan.

## **Documentation Requirements**

Correctly documenting patient encounters is critical for quality reporting and accurate reimbursement. This is key as health care reform continues to move toward quality-driven reimbursement.

- Documentation is legible.
- Ensure correct CPT, CPT II and ICD-10 codes are used.
- Blood pressure diagnosis is documented prior to June 30.
- All patient encounters, including telephone, fax and electronic message exchanges are documented.

## **Common HEDIS Barriers and Obstacles**

- Let us know if member attribution is incorrect (patient assigned to wrong PCP)
- Claim submitted without correct codes will not count toward the measure. This means we will be required to ask for the medical record.
- Claim submitted with inaccurate diagnosis code will incorrectly add to a measure.
- Not coding A1c or blood pressure values/results.
- Services not documented in the patient's medical chart.
- All required components of the measure not provided, e.g., diabetes diagnosis or hypertension without blood pressure reading.
- Records not transferred when patient changed PCP.
- Appointment availability when patient tries to schedule preventive services.
- Practice not seeing new patient in a timely manner.
- PCPs should include documentation received from specialists and other sources in outpatient chart i.e. eye exams, inpatient and discharge summaries, radiology, gastro, gaps summaries from health plan

## **Ways to improve Health Outcomes Survey and CAHPS Results**

### **Access to care**

- Ensure your patients get care quickly and efficiently by leaving open appointments on your schedule for sick/urgent needs
- Prompt patient to schedule their next routine care appointment after each visit
- If necessary, assist in the coordination of non-emergency transportation
- Provide a link to community resources to facilitate referrals
- Follow up with patients' specialists to confirm continuity of care

### **Educate your patients**

- Ask your patients what their major health concerns are
- Communicate at a level appropriate to the education level and in preferred language of the patient
- Encourage your patients to get the annual flu vaccine
- Discuss fall prevention and tactics
- Make mental health questions part of your patient care routine
- Bring up health topics like urinary incontinence and improving and maintaining physical health

### **Member Rewards Program 2026**

The Member Rewards Program offers incentive to members to complete an Annual Wellness Visit or In-Home Assessment each year. Members who complete one of these visits within the calendar year can earn a \$50 member reward. The reward is loaded to the Flexible Benefit Card after completing the necessary attestations. One reward per calendar year.



# Medical Record Collection/Delivery Methods

## Medical Record Confidentiality

Our health plan strictly maintains the confidentiality of any records, which are accessed only by authorized people adhering to the following guidelines. Records are:

- Kept in a safe and secure location.
- Appropriately destroyed when they are no longer needed for the purpose requested.
- Not further disclosed or otherwise distributed.

We are not asking for nor do we want any medical record information related to psychotherapy, HIV, substance abuse or developmental disabilities.

Further, your Provider Agreement stipulates that copies of members' medical records shall be provided to our health plan, or its respective designees, for quality improvement activities, e.g., HEDIS.

If you have questions concerning this request, please contact: [StarsAndHEDIS@mchs.com](mailto:StarsAndHEDIS@mchs.com).


## Medical Record Collection/Delivery Methods

Data collection methods include the following, as long as they meet HIPAA guidelines:

- Remote electronic medical record (EMR) system. EMR submissions, which are highly recommended, result in fewer visits and emails from our health plan.
- Fax.
- Hard copy, flash or CD delivered via postal service certified mail, or other signature-required service.
- Email encrypted to HIPAA standards.
- Schedule time with one of our HEDIS coordinators to come into your office to collect a copy of the records on-site.
- Ask that one of our HEDIS coordinators come by to pick up the records.

## Online Submission of Medical Records for Stars and HEDIS Gaps In Care

1. Access the Trinity Health Plan of Michigan Provider page at: <https://www.thpmedicare.org/michigan/for-providers>. Select the Go to Provider Portal button to navigate to the portal log-in screen. (For first time users, follow the easy steps to create a new account and log in. Please reach out to Provider Services for any issues with creating an account or account access.)
2. On the portal home page, select **Eligibility** from the navigation bar.



3. Locate the appropriate member from your roster OR use the search tool to locate the member record.

A screenshot of the 'Eligibility' search form. The form has a title 'Eligibility' in large, bold, black font. Below the title is a section labeled 'Select Provider:' with a dropdown menu showing 'All Providers'. Below this are four input fields: 'First Name:', 'Last Name:', 'Member ID(s):', and 'Date of Birth:'. There is also a 'Group:' label next to the 'Date of Birth:' field. At the bottom left is a green 'Search' button.


## Online Submission of Medical Records for Stars and HEDIS Gaps In Care (continued)

4. Select the member to open their details, then click the **Close Gaps In Care** button at the top of the record.




The screenshot shows a form titled "Eligibility". Below the title is a section labeled "Select Provider:" with a dropdown menu currently set to "All Providers". At the bottom of the form are two buttons: "Ask an Eligibility or Benefits Question" and "Close Gaps in Care". A red line originates from the text "Close Gaps In Care" in step 4 and points directly to the "Close Gaps in Care" button.

5. Enter content in all required fields on the **Close Gaps in Care** form.



The screenshot shows the "Close Gaps In Care" form. It has a title "Close Gaps In Care" and a section "Instructions". The instructions state: "This form is used to collect medical records related to the Healthcare Effectiveness Data and Information Set (HEDIS®) and closing gaps in care. HEDIS is a set of standardized performance measures. The purpose of HEDIS is to provide members with a means to assess the value they receive for their health care dollar and to hold health plans accountable for their performance. As a network provider, you may, at times, be required to assist in medical record data collection. To submit Gaps in Care Medical Records, please fill in all required fields below. Please make sure you add the requested records as an attachment prior to submitting the form. If you have questions about a request for records, please contact our Quality Management team at StarsAndHedis@mchs.com." Below the instructions is a section titled "Gaps in Care Form".

6. Select the **Attachments** tab. Add your medical record attachment(s), then select Add.



The screenshot shows the "Attachments" section of the form. It has a title "Attachments" and a paragraph: "Please return to the top of the page and select the Attachments tab to upload relevant medical records. Once all records have been added, return here to Submit." Below this is a section titled "Review and Submit" with a paragraph: "Review the information above and confirm it is correct and medical records are attached. Then click Submit to complete your Gaps In Care records request." At the bottom of this section is a green button labeled "Submit".

7. Once all attachments have been added, return to the **Close Gaps in Care** tab and click Submit.

## **Frequently Asked Questions**

### **Who reviews the medical records?**

Our health plan uses our own professionals and/or partners with expert organizations working on our behalf. All professionals reviewing the medical records will treat your patient's protected health information (PHI) with total protection and confidentiality.

### **Is a review of medical records permitted by HIPAA without a signed member release?**

HIPAA allows providers to disclose PHI to another covered entity without a signed release in reference to health care operations. These operations include activities such as quality assessment and improvement and health plan performance evaluations. HEDIS scores are a significant part of these activities.

### **When will I be asked to provide the records for HEDIS?**

Records may be requested throughout the year to close gaps in care and support on-going HEDIS performance monitoring.

### **Is my participation in data collection mandatory and what am I required to do?**

Yes. Network participants are contractually required to provide medical record information so we may fulfill our state and federal regulatory obligations. You and your staff are responsible for responding to our request for medical record documentation in a timely manner. You may provide the records yourself, or schedule time with one of our professionals to come into your office to collect a copy of the records on-site. If a patient included on the list is not part of your practice, you should notify us immediately.

### **Should I allow a record review for a patient who is no longer with the health plan or a patient who is deceased?**

Yes. Medical record reviews may require data collection on the services obtained over multiple years when the patient was receiving benefits from our health plan.

### **Am I required to provide medical records for a patient who was seen by a provider who has retired, died or moved?**

Yes. Data collection includes reviewing medical records as far back as 10 years (including before your patient was a health plan member). Archived medical records and data may be required to complete data collection.

If you have further questions, please contact: [StarsAndHEDIS@mchs.com](mailto:StarsAndHEDIS@mchs.com).

# Star Measures

|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Breast Cancer Screening (BCS-E)</b> | <b>Percentage of members 40-74 years of age who had a mammogram to screen for breast cancer any time on or between October 1 two years prior to the measurement year, and December 31 of the measurement year.</b><br><b>This measure evaluates primary screening, not diagnostic screenings.</b>                                                                                                                                                                                                                                                                                   |
| <b>Star Weight:</b>                    | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Provider Actions:</b>               | Mammogram to screen for cancer in the time period listed in measure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coding:</b>                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| CPT4                                   | 77061-77063<br>77065-77067                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Revenue                                | 0401<br>0403                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusions:</b>                     | Members with advanced illness and frailty.<br>Members with a history of bilateral or two unilateral mastectomies.<br>Members in hospice or palliative care.<br>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members deceased within the measurement period.<br>Members who had gender-affirming chest surgery with a diagnosis of gender dysphoria any time during the member's history through the end of the measurement period. |

## Plan All-Cause Readmission (PCR)

|                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Plan All-Cause Readmissions (PCR)</b> | <b>Members with an acute inpatient stay during the measurement year that were followed-up by an unplanned acute readmission for any diagnosis within 30-days and the predicted probability of an acute readmission.</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Star Weight:</b>                      | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Provider Action:</b>                  | A lower readmission rate and comprehensive diagnosis documentation will drive better scores for this measure.<br>Outreach to your patients and see them within 7 days of discharge.<br>Patients with multiple comorbidities are expected to return post inpatient or observation discharge at a higher rate. Ensure all suspect conditions are appropriately identified in the patient's medical record and claims.                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusions:</b>                       | Members in hospice/using hospice services during the measurement year.<br>Exclude acute hospitalizations with any the following: <ul style="list-style-type: none"> <li>- Member died during the inpatient stay</li> <li>- Member with a principal diagnosis of pregnancy</li> <li>- Planned admissions for: <ul style="list-style-type: none"> <li>- Chemotherapy maintenance</li> <li>- Principle diagnosis of rehabilitation</li> <li>- Organ transplant</li> <li>- Potentially planned procedure w/out a principal acute diagnosis</li> </ul> </li> </ul> Exclude the hospital stay if the direct transfer's discharge date occurs after Dec. 1 of the measurement year.<br>Exclude hospital stays where the Index Admission Date is the same as the Index Discharge Date. |

## Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC)

|                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC)</b> | <b>The percentage of emergency department visits for members 18 years and older who have multiple high-risk chronic conditions who had a follow-up service within 7 days of the ED visit. Chronic conditions include: COPD and Asthma, Alzheimer's disease and related disorders, Chronic Kidney disease, Depression, Heart Failure, MI, A-FIB, TIA and or Strokes</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Weight:</b>                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Provider Action:</b>                                                                                       | Perform follow up within 7 days of an ED visit for members with multiple chronic conditions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Qualifying Follow-Up Encounters:</b>                                                                       | <ul style="list-style-type: none"> <li>• Outpatient, telephone or telehealth visits</li> <li>• E-visit or virtual check-in</li> <li>• Transitional care management services</li> <li>• Case management visit</li> <li>• Complex care management service</li> <li>• Outpatient or telehealth behavioral health visit</li> <li>• Intensive outpatient encounter or partial hospitalization</li> <li>• Community mental health center visit</li> <li>• Electroconvulsive therapy</li> <li>• Behavior Health (BH) outpatient services</li> <li>• Substance use disorder services</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coding:*</b>                                                                                               | <p>CPT 4 - Outpatient visit, telephone visit, telehealth visit (e-visit or virtual check-in): 98000, 98001, 98002, 98003, 98004, 98005, 98006, 98007, 98008, 98009, 98010, 98011, 98012, 98013, 98014, 98015, 98016, 98966, 98967, 98968, 98970, 98971, 98972, 98980, 98981, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99242, 99243, 99244, 99245, 99341, 99342, 99344, 99345, 99347, 99348, 99349, 99350, 99381, 99382, 99383, 99384, 99385, 99386, 99387, 99391, 99392, 99393, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99421, 99422, 99423, 99429, 99441, 99442, 99443, 99455, 99456, 99457, 99458, 99483; Transitional Care Management Services: 99495, 99496; Case Management Encounter: 99366; Complex Care Management Services: 99439, 99487, 99489, 99490, 99491; Outpatient or telehealth behavioral health visit: 98000, 98001, 98002, 98003, 98004, 98005, 98006, 98007, 98960, 98961, 98962, 99078, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99242, 99243, 99244, 99245, 99341, 99342, 99344, 99345, 99347, 99348, 99349, 99350, 99381, 99382, 99383, 99384, 99385, 99386, 99387, 99391, 99392, 99393, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99483, 99492, 99493, 99494, 99510.</p> <p>HCPCS - Outpatient visit, telephone visit, telehealth visit (e-visit or virtual check-in): G0071, G0402, G0438, G0439, G0463, G2010, G2012, G2250, G2251, G2252, T1015<br/> <i>(NOTE: T1015 HCPCS code which identifies an all-inclusive clinic visit for services rendered at a Federally Qualified Health Center (FQHC));</i> Case Management Encounter: T1016, T1017, T2022, T2023; Complex Care Management Services: G0506; Outpatient or telehealth behavioral health visit: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020, T1015.</p> |
| <b>Exclusions:</b>                                                                                            | <p>Members in hospice/using hospice services during the measurement year.</p> <p>Members deceased within the measurement year.</p> <p>ED visits that result in an inpatient stay.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

\*Select codes only displayed here; for comprehensive code list, please contact us at StarsAndHEDIS@mchs.com

## Colorectal Cancer Screening (COL)

| Colorectal Cancer Screening (COL-E) | Percentage of members 45-75 years of age who had appropriate screening for colorectal cancer.                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Star Weight:                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Provider Actions:                   | Annual <b>gFOBT</b> or <b>FIT</b> during the measurement year.                                                                                                                                                                                                                                                                                                                                                              |
|                                     | Flexible <b>sigmoidoscopy</b> during the measurement year or the four years prior to the measurement year.                                                                                                                                                                                                                                                                                                                  |
|                                     | <b>FIT-DNA</b> during the measurement year or the 2 years prior                                                                                                                                                                                                                                                                                                                                                             |
|                                     | <b>Colonoscopy</b> during the measurement year or the nine years prior to the measurement year.                                                                                                                                                                                                                                                                                                                             |
|                                     | <b>CT Colonography</b> during the measurement year or the four years prior.                                                                                                                                                                                                                                                                                                                                                 |
| Coding:                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |
| LOINC                               | <b>Noninvasive colorectal cancer DNA and occult blood screening</b> [Interpretation] in Stool Narrative – 77353-1                                                                                                                                                                                                                                                                                                           |
|                                     | <b>Noninvasive colorectal cancer DNA and occult blood screening</b> [Presence] in Stool – 77354-9                                                                                                                                                                                                                                                                                                                           |
| CPT 4                               | <b>FOBT</b> – 82270, 82274                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                     | <b>Flexible Sigmoidoscopy</b> – 45330-45335, 45337-45338, 45340-45342, 45346-45347, 45349-45350                                                                                                                                                                                                                                                                                                                             |
|                                     | <b>FIT-DNA</b> - 81528                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                     | <b>Colonoscopy</b> – 44388, 44389, 44390, 44391, 44392, 44394, 44401-44408, 45378, 45379, 45380, 45381, 45382, 45384, 45385, 45386, 45388, 45389, 45390, 45391, 45392, 45393, 45398                                                                                                                                                                                                                                         |
|                                     | <b>CT Colonography</b> – 74261-74263                                                                                                                                                                                                                                                                                                                                                                                        |
| HCPCS                               | <b>FOBT</b> – G0328                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                     | <b>Flexible Sigmoidoscopy</b> – G0104                                                                                                                                                                                                                                                                                                                                                                                       |
|                                     | <b>Colonoscopy</b> – G0105, G0121                                                                                                                                                                                                                                                                                                                                                                                           |
| SNOMED CT US Edition                | <b>Stool DNA-based colorectal cancer screening positive</b> (finding) –708699002                                                                                                                                                                                                                                                                                                                                            |
|                                     | <b>Fecal occult blood trace finding</b> - 389076003                                                                                                                                                                                                                                                                                                                                                                         |
| ICD-9-CM Procedures                 | <b>Flexible Sigmoidoscopy</b> – 45.24<br><b>Colonoscopy</b> - 45.23                                                                                                                                                                                                                                                                                                                                                         |
| Exclusions:                         | Members receiving palliative care.<br>Members with advanced illness and frailty.<br>Members with a diagnosis of colorectal cancer or total colectomy.<br>Members in hospice.<br>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members deceased within the measurement year. |

## Controlling Blood Pressure (CBP)

| Controlling Blood Pressure (CBP)                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm Hg) during the measurement year. |  |
|-------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Star Weight:                                                                                                      | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                        |  |
| Provider Actions:                                                                                                 | The representative BP is the most recent BP reading during the measurement year on or after the second diagnosis of hypertension. If the initial BP is >140/90, retake the BP once the member has had time to rest.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                        |  |
| Coding                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                        |  |
| CPT 2                                                                                                             | Systolic BP <130 mmHg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3074F                                                                                                                                                                  |  |
|                                                                                                                   | Systolic BP 130-139 mmHg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 3075F                                                                                                                                                                  |  |
|                                                                                                                   | Systolic BP ≥140 mmHg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3077F                                                                                                                                                                  |  |
|                                                                                                                   | Diastolic BP <80 mmHg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3078F                                                                                                                                                                  |  |
|                                                                                                                   | Diastolic BP 80-89 mmHg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 3079F                                                                                                                                                                  |  |
|                                                                                                                   | Diastolic BP ≥90 mmHg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3080F                                                                                                                                                                  |  |
| LOINC                                                                                                             | Diastolic blood pressure–sitting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 8453-3                                                                                                                                                                 |  |
|                                                                                                                   | Diastolic blood pressure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 8462-4                                                                                                                                                                 |  |
|                                                                                                                   | Systolic blood pressure–sitting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 8459-0                                                                                                                                                                 |  |
|                                                                                                                   | Systolic blood pressure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 8480-6                                                                                                                                                                 |  |
| Exclusions:                                                                                                       | Palliative Care<br>Members with advanced illness and frailty.<br>Members in hospice.<br>Members with evidence of End-stage Renal Disease (ESRD) or kidney transplant on or prior to December 31 of the measurement year.<br>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members deceased within the measurement year.<br>Excluded BP readings:<br>- Taken during an acute inpatient stay or an ED visits.<br>- Taken on the same day as a diagnostic test or procedure that requires a medication on or one day before the day of the test or procedure, with the exception of fasting blood tests.<br>- Member-reported manual BPs. |                                                                                                                                                                        |  |
| * If more than one BP reading is collected on the same date record lowest systolic and lowest diastolic readings. |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                        |  |

## Transitions of Care (TRC)

| Transitions of Care (TRC) | Percentage of discharges for members 18 and older who had each of the following. Four rates are reported:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>Weight:</b>            | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |
| <b>Provider Action:</b>   | <ul style="list-style-type: none"> <li>• <b>Notification of Inpatient Admission.</b> Documentation of receipt of notification of inpatient admission on the day of admission or on the day of admission through 2 days after the admission (3 total days).</li> <li>• <b>Receipt of Discharge Information.</b> Documentation of receipt of discharge information on the day of discharge through 2 days after the discharge (3 total days).</li> <li>• At a minimum, the discharge information must include all of the following:               <ul style="list-style-type: none"> <li>• The practitioner responsible for the member's care during the inpatient stay.</li> <li>• Procedures or treatment provided.</li> <li>• Diagnoses at discharge.</li> <li>• Current medication list.</li> <li>• Testing results, or documentation of pending tests or no test pending.</li> <li>• Instructions for patient care post-discharge</li> </ul> </li> <li>• <b>Patient Engagement After Inpatient Discharge.</b> Documentation of patient engagement provided within 30 days after discharge.</li> <li>• <b>Medication Reconciliation Post-Discharge.</b> Documentation of medication reconciliation on the date of discharge through 30 days after discharge (31 total days).</li> </ul> |  |
| <b>Coding*:</b>           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |
| <b>CPT 2</b>              | Medication Reconciliation Post-Discharge: 1111F                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |
| <b>CPT 4</b>              | Patient Engagement After Inpatient Discharge: An outpatient visit, telephone visit, e-visit or virtual check-in: 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483, 98966-98968, 99441-99443, 98970-98972, 99421-99423, 99444, 99457.<br>Transitional care management: 99495, 99496.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  |
| <b>Exclusions:</b>        | Members deceased within the measurement year. Members in hospice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |

\*Select codes only displayed here; for comprehensive code list, please refer to NCQA.org, or contact us at StarsAndHEDIS@mchs.com



## Care for Patients with Diabetes

| Glycemic Status Assessment for Patients with Diabetes (GSD) [formerly Hemoglobin A1c for Patients with Diabetes (HBD) measure] | The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement year:<br>Glycemic Status <8.0%.<br>Glycemic Status >9.0%.                                           |       |
|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| <b>Star Weight:</b>                                                                                                            | 3                                                                                                                                                                                                                                                                                                                                  |       |
| <b>Provider Actions:</b>                                                                                                       | Annual documentation of the most recent date and result of the HbA1c test or GMI.                                                                                                                                                                                                                                                  |       |
| <b>Coding:</b>                                                                                                                 |                                                                                                                                                                                                                                                                                                                                    |       |
| <b>CPT 2</b>                                                                                                                   | Level <7.0%                                                                                                                                                                                                                                                                                                                        | 3044F |
|                                                                                                                                | Level >9.0%                                                                                                                                                                                                                                                                                                                        | 3046F |
|                                                                                                                                | Level >7.0<8.0%                                                                                                                                                                                                                                                                                                                    | 3051F |
|                                                                                                                                | Level > 8.0%<9.0%                                                                                                                                                                                                                                                                                                                  | 3052F |
| <b>CPT 4</b>                                                                                                                   | 83036-83037                                                                                                                                                                                                                                                                                                                        |       |
| <b>LOINC</b>                                                                                                                   | 4548-4, 17855-8, 4549-2, 17856-6, 96595-4                                                                                                                                                                                                                                                                                          |       |
| <b>Exclusions:</b>                                                                                                             | Members with advanced illness and frailty.<br>Member in hospice or palliative care.<br>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members deceased within the measurement year. |       |

| Eye Exam for Patients with Diabetes (EED) | The percentage of members 18-75 with diabetes (types 1 and 2) who had a retinal eye exam                                                                                                                                                                                                                                                                                                                                                                       |                     |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| <b>Star Weight:</b>                       | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                     |
| <b>Provider Actions:</b>                  | Annual documentation of most recent retinal or dilated eye exam or<br>Documentation of a negative retinal or dilated eye exam in prior year or<br>Chart/photograph of retinal abnormalities indicating date when the fundus photography was performed and evidence it was reviewed by an eye care professional (optometrist or ophthalmologist) in current year.                                                                                               |                     |
| <b>Coding:</b>                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                     |
| <b>CPT 2</b>                              | Diabetic Retinal Screening with Eye Care Professional:                                                                                                                                                                                                                                                                                                                                                                                                         | 2022F, 2024F, 2026F |
|                                           | Negative Indicators for Diabetic Retinopathy                                                                                                                                                                                                                                                                                                                                                                                                                   | 2023F, 2025F        |
|                                           | Diabetic Retinal Screening Negative:                                                                                                                                                                                                                                                                                                                                                                                                                           | 2033F               |
| <b>Exclusions:</b>                        | Member in hospice or palliative care.<br>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members deceased within the measurement year.<br>Members with advanced illness and frailty.<br>Members with bilateral eye enucleation any time during the member's history through December 31 of the measurement year. |                     |

## Kidney Health Evaluation for Patients With Diabetes (KED)

| Kidney Health Evaluation for Patients With Diabetes (KED) | The percentage of members 18–85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin:creatinine ratio (uACR), during the measurement year.                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Star Weight:</b>                                       | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Provider Action:</b>                                   | Annual documentation of both an eGFR and a uACR during the measurement year on the same or different dates of service.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Reported Rates</b>                                     | Two elements are required during the measurement year on same or different dates of service: <ol style="list-style-type: none"> <li>At least one estimated Glomerular Filtration Rate (eGFR) lab test.</li> <li>At least one uACR identified by both a quantitative urine albumin test and a urine creatinine test with service dates four or less days apart.</li> </ol>                                                                                                                                                                                                                                                            |
| <b>Coding:</b>                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| CPT - eGFR Lab Test                                       | 80047, 80048, 80050, 80053, 80069, 82565                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| CPT - Quantitative Urine Albumin lab test                 | 82043                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| CPT - Urine creatinine lab test                           | 82570                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>LOINC</b>                                              | 50044-7, 50210-4, 50384-7, 62238-1, 69405-9, 70969-1, 77147-7, 94677-2, 98979-8, 98980-6; 100158-5, 14957-5, 1754-1, 21059-1, 30003-8, 43605-5, 53530-2, 53531-0, 57369-1, 89999-7; 20624-3, 2161-8, 35674-1, 39982-4, 57344-4, 57346-9, 58951-5; 13705-9, 14958-3, 14959-1, 30000-4, 44292-1, 59159-4, 76401-9, 77253-3, 77254-1, 89998-9, 9318-7                                                                                                                                                                                                                                                                                   |
| <b>Exclusions:</b>                                        | Members in hospice.<br>Members with advanced illness and frailty.<br>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members receiving palliative care during the measurement year.<br>Members with a diagnosis of ESRD any time during the member's history on or prior to December 31 of the measurement year.<br>Members who had dialysis any time during the member's history on or prior to December 31 of the measurement year.<br>Members deceased during the measurement year. |

## Osteoporosis Management in Women Who Had a Fracture (OMW)

| Osteoporosis Management in Women Who Had a Fracture (OMW) |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | The percentage of women 67-85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis in the six months after the fracture. Note: Fractures of finger, face and skull are not included in this measure. |  |
|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Star Weight:                                              | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                       |  |
| Provider Action:                                          | Perform Bone Mineral Density (BMD) test or prescribe medication therapy to treat osteoporosis within 6 months of a fracture. Allowable every 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                       |  |
| Coding:                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                       |  |
| CPT4                                                      | Bone Mineral Density Test: 76977, 77080-77081, 77085 - 77086                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                       |  |
| HCPCS                                                     | Injection, Denosumab, 1 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | J0897                                                                                                                                                                                                                                                                                                 |  |
|                                                           | Injection, Ibandronate sodium, 1 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | J1740                                                                                                                                                                                                                                                                                                 |  |
|                                                           | Injection, Teriparatide, 10 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | J3110-J3111                                                                                                                                                                                                                                                                                           |  |
|                                                           | Injection, Zoledronic acid ,1 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | J3489                                                                                                                                                                                                                                                                                                 |  |
|                                                           | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 m                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Q5136                                                                                                                                                                                                                                                                                                 |  |
| ICD10PCS                                                  | Ultrasonography of Right Shoulder, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | BP48ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Left Shoulder, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | BP49ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Right Elbow, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | BP4GZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Left Elbow, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | BP4HZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Right Wrist, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | BP4LZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Left Wrist, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | BP4MZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Right Hand, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | BP4NZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Ultrasonography of Left Hand, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | BP4PZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Right Hip, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | BQ00ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Left Hip, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | BQ01ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Right Femur, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | BQ03ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Left Femur, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | BQ04ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Cervical Spine, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | BR00ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Thoracic Spine, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | BR07ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Lumbar Spine, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | BR09ZZ1                                                                                                                                                                                                                                                                                               |  |
|                                                           | Plain Radiography of Whole Spine, Densitometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | BR0GZZ1                                                                                                                                                                                                                                                                                               |  |
| Medications                                               | Notation of the following prescribed medications listed below:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                       |  |
|                                                           | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Prescription                                                                                                                                                                                                                                                                                          |  |
|                                                           | Bisphosphonates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • Alendronate<br>• Alendronate-cholecalciferol<br>• Ibandronate<br><br>• Risedronate<br>• Zoledronic acid                                                                                                                                                                                             |  |
|                                                           | Other agents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | • Abaloparatide<br>• Denosumab<br>• Raloxifene<br><br>• Romosozumab<br>• Teriparatide                                                                                                                                                                                                                 |  |
| Exclusions:                                               | Members with advanced illness and frailty.<br>Members who had a Bone Mineral Density Test during the 730 days (24 months) prior to the Index Episode Start Date (IESD).<br>Members who had a claim/encounter for osteoporosis therapy during the 365 days (12 months) prior to the IESD.<br>Members who received a dispensed prescription or had an active prescription to treat osteoporosis during the 365 days (12 months) prior to the IESD.<br>Member in hospice or palliative care.<br>Members 67 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).<br>Members deceased within the measurement year. |                                                                                                                                                                                                                                                                                                       |  |

## Statin Therapy for Patients with Cardiovascular Disease (SPC)

| Statin Therapy for Patients with Cardiovascular Disease (SPC) | The percentage of males 21-75 years of age and females 40-75 years of age with clinical atherosclerotic cardiovascular disease (ASCVD) who receive a high or moderate-intensity statin medication during the measurement year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------|-------------------------------|-------------------------|------------------------------------|-------------------------|---------------------|-------------------------------|-----------------------------------|-------------------------|------------------------------------|------------------------|------------------------|----------------------------------|------------------------|--------------------|------------------------|-----------------------|
| Star Weight:                                                  | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
| Provider Action:                                              | <p>Encourage the member to adhere at least 80% or more to their statin medication. Prescribe at least one high-intensity or moderate-intensity statin medication during the measurement year:</p> <table> <tr> <th>Description</th><th>Prescription</th></tr> <tr> <td rowspan="5">High-intensity statin therapy</td><td>• Atorvastatin 40-80 mg</td></tr> <tr> <td>• Amlodipine-atorvastatin 40-80 mg</td></tr> <tr> <td>• Rosuvastatin 20-40 mg</td></tr> <tr> <td>• Simvastatin 80 mg</td></tr> <tr> <td>• Ezetimibe-simvastatin 80 mg</td></tr> <tr> <td rowspan="9">Moderate-intensity statin therapy</td><td>• Atorvastatin 10-20 mg</td></tr> <tr> <td>• Amlodipine-atorvastatin 10-20 mg</td></tr> <tr> <td>• Rosuvastatin 5-10 mg</td></tr> <tr> <td>• Simvastatin 20-40 mg</td></tr> <tr> <td>• Ezetimibe-simvastatin 20-40 mg</td></tr> <tr> <td>• Pravastatin 40-80 mg</td></tr> <tr> <td>• Lovastatin 40 mg</td></tr> <tr> <td>• Fluvastatin 40-80 mg</td></tr> <tr> <td>• Pitavastatin 1-4 mg</td></tr> </table> | Description | Prescription | High-intensity statin therapy | • Atorvastatin 40-80 mg | • Amlodipine-atorvastatin 40-80 mg | • Rosuvastatin 20-40 mg | • Simvastatin 80 mg | • Ezetimibe-simvastatin 80 mg | Moderate-intensity statin therapy | • Atorvastatin 10-20 mg | • Amlodipine-atorvastatin 10-20 mg | • Rosuvastatin 5-10 mg | • Simvastatin 20-40 mg | • Ezetimibe-simvastatin 20-40 mg | • Pravastatin 40-80 mg | • Lovastatin 40 mg | • Fluvastatin 40-80 mg | • Pitavastatin 1-4 mg |
| Description                                                   | Prescription                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
| High-intensity statin therapy                                 | • Atorvastatin 40-80 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Amlodipine-atorvastatin 40-80 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Rosuvastatin 20-40 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Simvastatin 80 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Ezetimibe-simvastatin 80 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
| Moderate-intensity statin therapy                             | • Atorvastatin 10-20 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Amlodipine-atorvastatin 10-20 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Rosuvastatin 5-10 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Simvastatin 20-40 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Ezetimibe-simvastatin 20-40 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Pravastatin 40-80 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Lovastatin 40 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Fluvastatin 40-80 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
|                                                               | • Pitavastatin 1-4 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |
| Exclusions (With appropriate diagnosis code on claim):        | <p>Members with advanced illness and frailty.</p> <p>Myalgia or rhabdomyolysis caused by a statin any time during the member's history through December 31 of the measurement year.</p> <p>Members with ESRD or dialysis during the measurement year or the year prior.</p> <p>Members diagnosed with Cirrhosis during the measurement year or the year prior to the measurement year.</p> <p>Members dispensed with at least one prescription for clomiphene (Estrogen Agonist) during the measurement year or the year prior to the measurement year.</p> <p>Member diagnosed with Muscular Pain and Disease to include Myalgia, Myopathy, Rhabdomyolysis during the measurement year.</p> <p>Member in hospice or palliative care.</p> <p>Members 66 years of age and older as of December 31 of the measurement year who are enrolled in an I-SNP any time during the measurement year or living long term in an institution (LTI).</p> <p>Members deceased during the measurement year.</p>                               |             |              |                               |                         |                                    |                         |                     |                               |                                   |                         |                                    |                        |                        |                                  |                        |                    |                        |                       |

## Part D Measures

| Medication Adherence - Cholesterol       | The percentage of Part D beneficiaries aged 18 or older who had at least two fills of cholesterol medication (a statin drug) on unique dates of service who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication.                                                                                                                                                                                                                                                                                                                                                                                                    |                                     |  |  |                                          |              |                              |             |             |                                     |                         |  |  |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--|--|------------------------------------------|--------------|------------------------------|-------------|-------------|-------------------------------------|-------------------------|--|--|
| Star Weight:                             | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                     |  |  |                                          |              |                              |             |             |                                     |                         |  |  |
| Provider Action:                         | <p>Always prescribe 90 days when possible. Encourage patients to adhere to their prescribed statin medication at 80% or more throughout the year for the following medications.</p> <p><b>Table STATINS: Statins<sup>a</sup></b></p> <table><tr><th colspan="3">Statin Medications and Combinations</th></tr><tr><td>atorvastatin (+/- amlodipine, ezetimibe)</td><td>pitavastatin</td><td>rosuvastatin (+/- ezetimibe)</td></tr><tr><td>fluvastatin</td><td>pravastatin</td><td>simvastatin (+/- ezetimibe, niacin)</td></tr><tr><td>lovastatin (+/- niacin)</td><td></td><td></td></tr></table> <p><sup>a</sup> The active ingredients are limited to oral formulations only.</p> | Statin Medications and Combinations |  |  | atorvastatin (+/- amlodipine, ezetimibe) | pitavastatin | rosuvastatin (+/- ezetimibe) | fluvastatin | pravastatin | simvastatin (+/- ezetimibe, niacin) | lovastatin (+/- niacin) |  |  |
| Statin Medications and Combinations      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                     |  |  |                                          |              |                              |             |             |                                     |                         |  |  |
| atorvastatin (+/- amlodipine, ezetimibe) | pitavastatin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | rosuvastatin (+/- ezetimibe)        |  |  |                                          |              |                              |             |             |                                     |                         |  |  |
| fluvastatin                              | pravastatin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | simvastatin (+/- ezetimibe, niacin) |  |  |                                          |              |                              |             |             |                                     |                         |  |  |
| lovastatin (+/- niacin)                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                     |  |  |                                          |              |                              |             |             |                                     |                         |  |  |
| Exclusions:                              | Members enrolled in hospice any time during the measurement period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                     |  |  |                                          |              |                              |             |             |                                     |                         |  |  |

| Medication Adherence – Diabetes                                                                                                                                                               | The percentage of Medicare Part D beneficiaries, 18 years or older, with at least two diabetes medication fills on unique dates of service during the measurement period who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------------------|----------------------------------------|-----------------------------|-----------------------------------------------|-------------------------------------------------------------|-----------------------------------------------|---------------------------|--------------------------|------------------------------------------------|--|-------------------------------------------------------|----------------------------------------------------------|------------------------------------|--|------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------------------------------|--|--------------------------|--------------|-------------|-------------|-----------|-------------|-------------|--|-------------------------------------------|--|-------------|----------------------------|-----------------------------------------------|--|---------------|--------------------------------------------|-------------------------------|--------------------------------------------|--------------------------------------------|--|
| Star Weight:                                                                                                                                                                                  | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| Provider Action:                                                                                                                                                                              | <p>Always prescribe 90 days when possible. Encourage patients to adhere to their prescribed drug therapy 80% or more throughout the year for the following medications: Biguanides, Sulfonylureas, Thiazolidinediones, DPP-IV inhibitors, Incretin Mimetics, Meglitinides, and SGLT2 inhibitors:</p> <p><b>Table BG: Biguanides<sup>a,b</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">Biguanide Medications and Combinations</th> </tr> </thead> <tbody> <tr> <td colspan="2">metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin)</td> </tr> </tbody> </table> <p>a Active ingredients are limited to oral formulations only.</p> <p>b Excludes nutritional supplement/dietary management combination products.</p> <p><b>Table SFU: Sulfonylureas<sup>a</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">Sulfonylurea Medications and Combinations</th> </tr> </thead> <tbody> <tr> <td>chlorpropamide<sup>b</sup></td><td>glyburide (+/- metformin)</td> </tr> <tr> <td>glimepiride (+/- pioglitazone, rosiglitazone<sup>b</sup>)</td><td>tolazamide</td> </tr> <tr> <td>glipizide (+/- metformin)</td><td>tolbutamide<sup>b</sup></td> </tr> </tbody> </table> <p>a Active ingredients are limited to oral formulations only.</p> <p>b There are no active NDCs for chlorpropamide, glimepiride/rosiglitazone, or tolbutamide.</p> <p><b>Table TZD: Thiazolidinediones<sup>a</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">Thiazolidinedione Medications and Combinations</th> </tr> </thead> <tbody> <tr> <td>pioglitazone (+/- alogliptin, glimepiride, metformin)</td><td>rosiglitazone (+/- glimepiride<sup>b</sup>, metformin)</td> </tr> </tbody> </table> <p>a Active ingredients are limited to oral formulations only.</p> <p>b There are no active NDCs for rosiglitazone/glimepiride.</p> <p><b>Table DPP4: DPP-4 Inhibitors<sup>a</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">DPP-4 Medications and Combinations</th> </tr> </thead> <tbody> <tr> <td>alogliptin (+/- metformin, pioglitazone)</td><td>saxagliptin (+/- metformin, dapagliflozin)</td> </tr> <tr> <td>linagliptin (+/- empagliflozin, metformin)</td><td>sitagliptin (+/- metformin, ertugliflozin)</td> </tr> </tbody> </table> <p>a Active ingredients are limited to oral formulations only.</p> <p><b>Table GIP/GLP1: GLP-1 Receptor Agonists<sup>c</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">GIP/GLP-1 Receptor Agonists Medications</th> </tr> </thead> <tbody> <tr> <td>albiglutide<sup>b</sup></td><td>lixisenatide</td> </tr> <tr> <td>dulaglutide</td><td>semaglutide</td> </tr> <tr> <td>exenatide</td><td>tirzepatide</td> </tr> <tr> <td>liraglutide</td><td></td> </tr> </tbody> </table> <p>a Excludes products indicated for weight loss.</p> <p>b No active NDCs for albiglutide.</p> <p><b>Table MEG: Meglitinides<sup>a</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">Meglitinides Medications and Combinations</th> </tr> </thead> <tbody> <tr> <td>nateglinide</td><td>repaglinide (+/-metformin)</td> </tr> </tbody> </table> <p>a Active ingredients are limited to oral formulations only.</p> <p><b>Table SGLT2: SGLT2 Inhibitors<sup>a</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">SGLT2 Inhibitors Medications and Combinations</th> </tr> </thead> <tbody> <tr> <td>bexagliflozin</td><td>dapagliflozin (+/- metformin, saxagliptin)</td> </tr> <tr> <td>canagliflozin (+/- metformin)</td><td>empagliflozin (+/- metformin, linagliptin)</td> </tr> <tr> <td>ertugliflozin (+/- sitagliptin, metformin)</td><td></td> </tr> </tbody> </table> <p>a Active ingredients are limited to oral formulations only.</p> | Biguanide Medications and Combinations |  | metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin) |                   | Sulfonylurea Medications and Combinations |                                        | chlorpropamide <sup>b</sup> | glyburide (+/- metformin)                     | glimepiride (+/- pioglitazone, rosiglitazone <sup>b</sup> ) | tolazamide                                    | glipizide (+/- metformin) | tolbutamide <sup>b</sup> | Thiazolidinedione Medications and Combinations |  | pioglitazone (+/- alogliptin, glimepiride, metformin) | rosiglitazone (+/- glimepiride <sup>b</sup> , metformin) | DPP-4 Medications and Combinations |  | alogliptin (+/- metformin, pioglitazone) | saxagliptin (+/- metformin, dapagliflozin) | linagliptin (+/- empagliflozin, metformin) | sitagliptin (+/- metformin, ertugliflozin) | GIP/GLP-1 Receptor Agonists Medications |  | albiglutide <sup>b</sup> | lixisenatide | dulaglutide | semaglutide | exenatide | tirzepatide | liraglutide |  | Meglitinides Medications and Combinations |  | nateglinide | repaglinide (+/-metformin) | SGLT2 Inhibitors Medications and Combinations |  | bexagliflozin | dapagliflozin (+/- metformin, saxagliptin) | canagliflozin (+/- metformin) | empagliflozin (+/- metformin, linagliptin) | ertugliflozin (+/- sitagliptin, metformin) |  |
| Biguanide Medications and Combinations                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin) |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| Sulfonylurea Medications and Combinations                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| chlorpropamide <sup>b</sup>                                                                                                                                                                   | glyburide (+/- metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| glimepiride (+/- pioglitazone, rosiglitazone <sup>b</sup> )                                                                                                                                   | tolazamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| glipizide (+/- metformin)                                                                                                                                                                     | tolbutamide <sup>b</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| Thiazolidinedione Medications and Combinations                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| pioglitazone (+/- alogliptin, glimepiride, metformin)                                                                                                                                         | rosiglitazone (+/- glimepiride <sup>b</sup> , metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| DPP-4 Medications and Combinations                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| alogliptin (+/- metformin, pioglitazone)                                                                                                                                                      | saxagliptin (+/- metformin, dapagliflozin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| linagliptin (+/- empagliflozin, metformin)                                                                                                                                                    | sitagliptin (+/- metformin, ertugliflozin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| GIP/GLP-1 Receptor Agonists Medications                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| albiglutide <sup>b</sup>                                                                                                                                                                      | lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| dulaglutide                                                                                                                                                                                   | semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| exenatide                                                                                                                                                                                     | tirzepatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| liraglutide                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| Meglitinides Medications and Combinations                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| nateglinide                                                                                                                                                                                   | repaglinide (+/-metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| SGLT2 Inhibitors Medications and Combinations                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| bexagliflozin                                                                                                                                                                                 | dapagliflozin (+/- metformin, saxagliptin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| canagliflozin (+/- metformin)                                                                                                                                                                 | empagliflozin (+/- metformin, linagliptin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| ertugliflozin (+/- sitagliptin, metformin)                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| Exclusions:                                                                                                                                                                                   | <p>Beneficiaries who have one or more of the following prescriptions for insulin in the measurement period listed below.</p> <p><b>Table INSULINS: Insulin Exclusion<sup>a,b</sup></b></p> <table border="1"> <thead> <tr> <th colspan="2">Insulins</th> </tr> </thead> <tbody> <tr> <td>insulin aspart (+/- insulin aspart protamine, niacinamide)</td><td>insulin glulisine</td> </tr> <tr> <td>insulin degludec (+/- liraglutide)</td><td>insulin isophane (+/- regular insulin)</td> </tr> <tr> <td>insulin detemir</td><td>insulin lispro (+/- insulin lispro protamine)</td> </tr> <tr> <td>insulin glargine (+/- lixisenatide)</td><td>insulin regular (including inhalation powder)</td> </tr> </tbody> </table> <p>a Active ingredients are limited to inhaled and injectable formulations</p> <p>Beneficiaries enrolled in hospice any time during the measurement period.<br/>Beneficiaries that have ESRD</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Insulins                               |  | insulin aspart (+/- insulin aspart protamine, niacinamide)                                                                                                                                    | insulin glulisine | insulin degludec (+/- liraglutide)        | insulin isophane (+/- regular insulin) | insulin detemir             | insulin lispro (+/- insulin lispro protamine) | insulin glargine (+/- lixisenatide)                         | insulin regular (including inhalation powder) |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| Insulins                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| insulin aspart (+/- insulin aspart protamine, niacinamide)                                                                                                                                    | insulin glulisine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| insulin degludec (+/- liraglutide)                                                                                                                                                            | insulin isophane (+/- regular insulin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| insulin detemir                                                                                                                                                                               | insulin lispro (+/- insulin lispro protamine)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |
| insulin glargine (+/- lixisenatide)                                                                                                                                                           | insulin regular (including inhalation powder)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                        |  |                                                                                                                                                                                               |                   |                                           |                                        |                             |                                               |                                                             |                                               |                           |                          |                                                |  |                                                       |                                                          |                                    |  |                                          |                                            |                                            |                                            |                                         |  |                          |              |             |             |           |             |             |  |                                           |  |             |                            |                                               |  |               |                                            |                               |                                            |                                            |  |

| Medication Adherence - Hypertension-RAS Antagonists | The percentage of Medicare Part D beneficiaries, 18 years or older, with at least two RAS antagonist medication fills on unique dates of service during the measurement period, who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|----------------------|-------------------------------------|--|----------------------------------|--|---------------------------------|--------------------------------------|---------------------------------------|------------------------------------|--------------------------------------|--------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------|--|--------------------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------------|--------------------------------------|-------------------------------------|----------|------------------------------|
| Star Weight:                                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| Provider Action:                                    | <p>Always prescribe 90 days when possible. Encourage patients to adhere to their prescribed ACE inhibitors, ARBs, or Direct Renin Inhibitors 80% or more throughout the year.</p> <p><b>Table RASA: Renin Angiotensin System (RAS) Antagonists</b><br/>a, b</p> <table><tr><th colspan="2">Direct Renin Inhibitor Medications and Combinations</th></tr><tr><td colspan="2">aliskiren (+/- hydrochlorothiazide)</td></tr><tr><th colspan="2">ARB Medications and Combinations</th></tr><tr><td>azilsartan (+/- chlorthalidone)</td><td>irbesartan (+/- hydrochlorothiazide)</td></tr><tr><td>candesartan (+/- hydrochlorothiazide)</td><td>losartan (+/- hydrochlorothiazide)</td></tr><tr><td>eprosartan (+/- hydrochlorothiazide)</td><td>olmesartan (+/- amlodipine, hydrochlorothiazide)</td></tr><tr><td>telmisartan (+/- amlodipine, hydrochlorothiazide)</td><td>valsartan (+/- amlodipine, hydrochlorothiazide nebivolol)</td></tr><tr><th colspan="2">ACE Inhibitor Medications and Combination Products</th></tr><tr><td>benazepril (+/- amlodipine, hydrochlorothiazide)</td><td>lisinopril (+/- hydrochlorothiazide)</td></tr><tr><td>captopril (+/- hydrochlorothiazide)</td><td>moexipril (+/- hydrochlorothiazide)</td></tr><tr><td>enalapril (+/- hydrochlorothiazide)</td><td>perindopril (+/- amlodipine)</td></tr><tr><td>fosinopril (+/- hydrochlorothiazide)</td><td>quinapril (+/- hydrochlorothiazide)</td></tr><tr><td>ramipril</td><td>trandolapril (+/- verapamil)</td></tr></table> <p>a Active ingredients are limited to oral formulations only.<br/>b Excludes nutritional supplement/dietary management combination</p> | Direct Renin Inhibitor Medications and Combinations |                      | aliskiren (+/- hydrochlorothiazide) |  | ARB Medications and Combinations |  | azilsartan (+/- chlorthalidone) | irbesartan (+/- hydrochlorothiazide) | candesartan (+/- hydrochlorothiazide) | losartan (+/- hydrochlorothiazide) | eprosartan (+/- hydrochlorothiazide) | olmesartan (+/- amlodipine, hydrochlorothiazide) | telmisartan (+/- amlodipine, hydrochlorothiazide) | valsartan (+/- amlodipine, hydrochlorothiazide nebivolol) | ACE Inhibitor Medications and Combination Products |  | benazepril (+/- amlodipine, hydrochlorothiazide) | lisinopril (+/- hydrochlorothiazide) | captopril (+/- hydrochlorothiazide) | moexipril (+/- hydrochlorothiazide) | enalapril (+/- hydrochlorothiazide) | perindopril (+/- amlodipine) | fosinopril (+/- hydrochlorothiazide) | quinapril (+/- hydrochlorothiazide) | ramipril | trandolapril (+/- verapamil) |
| Direct Renin Inhibitor Medications and Combinations |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| aliskiren (+/- hydrochlorothiazide)                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| ARB Medications and Combinations                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| azilsartan (+/- chlorthalidone)                     | irbesartan (+/- hydrochlorothiazide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| candesartan (+/- hydrochlorothiazide)               | losartan (+/- hydrochlorothiazide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| eprosartan (+/- hydrochlorothiazide)                | olmesartan (+/- amlodipine, hydrochlorothiazide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| telmisartan (+/- amlodipine, hydrochlorothiazide)   | valsartan (+/- amlodipine, hydrochlorothiazide nebivolol)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| ACE Inhibitor Medications and Combination Products  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| benazepril (+/- amlodipine, hydrochlorothiazide)    | lisinopril (+/- hydrochlorothiazide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| captopril (+/- hydrochlorothiazide)                 | moexipril (+/- hydrochlorothiazide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| enalapril (+/- hydrochlorothiazide)                 | perindopril (+/- amlodipine)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| fosinopril (+/- hydrochlorothiazide)                | quinapril (+/- hydrochlorothiazide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| ramipril                                            | trandolapril (+/- verapamil)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| Exclusions:                                         | <p>Beneficiaries that received one of more prescription claims for Sacubitril/Valsartan.</p> <p><b>Table SAC-VAL: Sacubitril/Valsartan Exclusion</b></p> <table><tr><th>ARB/Neprilysin Inhibitor Combination Medication</th></tr><tr><td>sacubitril/valsartan</td></tr></table> <p>Beneficiaries enrolled in hospice any time during the measurement period<br/>Beneficiaries that have ESRD</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ARB/Neprilysin Inhibitor Combination Medication     | sacubitril/valsartan |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| ARB/Neprilysin Inhibitor Combination Medication     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |
| sacubitril/valsartan                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                     |                      |                                     |  |                                  |  |                                 |                                      |                                       |                                    |                                      |                                                  |                                                   |                                                           |                                                    |  |                                                  |                                      |                                     |                                     |                                     |                              |                                      |                                     |          |                              |

| Statin Therapy for Patients with Diabetes (SUPD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | The percentage of Medicare Part D beneficiaries, ages 40-75 years, dispensed at least two diabetes medication fills who received a statin medication fill.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------|----------------------------------------|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------|--------------------------------------------|-------------|-------------------------------------|-----------------------------|------------------------------------------------------------|------------|---------------------------|---------------------------|--------------------------|------------------------------------------|--|--|-------------|-----------------------------|--|-------------------------------|--|--|----------|----------|--|------------------------------------------------|--|--|-------------------------------------------------------|----------------------------------------------------------|--|---------------------------------------------------------|--|--|--------------------------|------------------------------------|-------------|-------------|-------------------------------------|-------------|-----------|--|--|----------------|--|--|-------------|--|--|----------------------------------------------|--|--|------------------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|--|--|--------------------------------------|--|--|------------------------------------------------------------|-------------------------------------|----------------------------------------|------------------------------------|---------------------|-----------------------------------------------|-----------------|--|-----------------------------------------------|----------------------------------------------|--|--|---------------|---------------------------------------------------------|--------------------------------------------|-------------------------------|---------------------------------------------------------|--|
| Star Weight:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| Provider Action:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Table DIABETES: Diabetes Medications <sup>a,b,c,d</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <table><tr><th colspan="3">Biguanide Medications and Combinations</th></tr><tr><td colspan="3">metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin)</td></tr><tr><th colspan="3">Sulfonylureas Medications and Combinations</th></tr><tr><td>chlorpropamide<sup>e</sup></td><td>glimepiride (+/- pioglitazone, rosiglitazone)<sup>e</sup></td><td>tolazamide</td></tr><tr><td>glipizide (+/- metformin)</td><td>glyburide (+/- metformin)</td><td>tolbutamide<sup>e</sup></td></tr><tr><th colspan="3">Meglitinide Medications and Combinations</th></tr><tr><td>nateglinide</td><td>repaglinide (+/- metformin)</td><td></td></tr><tr><th colspan="3">Alpha- Glucosidase Inhibitors</th></tr><tr><td>acarbose</td><td>miglitol</td><td></td></tr><tr><th colspan="3">Thiazolidinedione Medications and Combinations</th></tr><tr><td>pioglitazone (+/- alogliptin, glimepiride, metformin)</td><td>rosiglitazone (+/- glimepiride<sup>e</sup>, metformin)</td><td></td></tr><tr><th colspan="3">GIP/GLP-1 Receptor Agonist Medications and Combinations</th></tr><tr><td>albiglutide<sup>e</sup></td><td>liraglutide (+/- insulin degludec)</td><td>semaglutide</td></tr><tr><td>dulaglutide</td><td>lixisenatide (+/- insulin glargine)</td><td>tirzepatide</td></tr><tr><td>exenatide</td><td></td><td></td></tr><tr><th colspan="3">Amylin Analogs</th></tr><tr><td>pramlintide</td><td></td><td></td></tr><tr><th colspan="3">DPP-4 Inhibitor Medications and Combinations</th></tr><tr><td>alogliptin (+/- metformin, pioglitazone)</td><td>saxagliptin (+/-dapagliflozin, metformin)</td><td>sitagliptin (+/- metformin, ertugliflozin)</td></tr><tr><td>linagliptin (+/- empagliflozin, metformin)</td><td></td><td></td></tr><tr><th colspan="3">Insulin Medications and Combinations</th></tr><tr><td>insulin aspart (+/- insulin aspart protamine, niacinamide)</td><td>insulin glargine (+/- lixisenatide)</td><td>insulin isophane (+/- regular insulin)</td></tr><tr><td>insulin degludec (+/- liraglutide)</td><td>ininsulin glulisine</td><td>insulin lispro (+/- insulin lispro protamine)</td></tr><tr><td>insulin detemir</td><td></td><td>insulin regular (including inhalation powder)</td></tr><tr><th colspan="3">SGLT2 Inhibitor Medications and Combinations</th></tr><tr><td>bexagliflozin</td><td>dapagliflozin (+/- metformin, saxagliptin)<sup>f</sup></td><td>ertugliflozin (+/- sitagliptin, metformin)</td></tr><tr><td>canagliflozin (+/- metformin)</td><td>empagliflozin (+/- linagliptin, metformin)<sup>f</sup></td><td></td></tr></table> |                                                            |                                            | Biguanide Medications and Combinations |  |  | metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin) |              |                              | Sulfonylureas Medications and Combinations |             |                                     | chlorpropamide <sup>e</sup> | glimepiride (+/- pioglitazone, rosiglitazone) <sup>e</sup> | tolazamide | glipizide (+/- metformin) | glyburide (+/- metformin) | tolbutamide <sup>e</sup> | Meglitinide Medications and Combinations |  |  | nateglinide | repaglinide (+/- metformin) |  | Alpha- Glucosidase Inhibitors |  |  | acarbose | miglitol |  | Thiazolidinedione Medications and Combinations |  |  | pioglitazone (+/- alogliptin, glimepiride, metformin) | rosiglitazone (+/- glimepiride <sup>e</sup> , metformin) |  | GIP/GLP-1 Receptor Agonist Medications and Combinations |  |  | albiglutide <sup>e</sup> | liraglutide (+/- insulin degludec) | semaglutide | dulaglutide | lixisenatide (+/- insulin glargine) | tirzepatide | exenatide |  |  | Amylin Analogs |  |  | pramlintide |  |  | DPP-4 Inhibitor Medications and Combinations |  |  | alogliptin (+/- metformin, pioglitazone) | saxagliptin (+/-dapagliflozin, metformin) | sitagliptin (+/- metformin, ertugliflozin) | linagliptin (+/- empagliflozin, metformin) |  |  | Insulin Medications and Combinations |  |  | insulin aspart (+/- insulin aspart protamine, niacinamide) | insulin glargine (+/- lixisenatide) | insulin isophane (+/- regular insulin) | insulin degludec (+/- liraglutide) | ininsulin glulisine | insulin lispro (+/- insulin lispro protamine) | insulin detemir |  | insulin regular (including inhalation powder) | SGLT2 Inhibitor Medications and Combinations |  |  | bexagliflozin | dapagliflozin (+/- metformin, saxagliptin) <sup>f</sup> | ertugliflozin (+/- sitagliptin, metformin) | canagliflozin (+/- metformin) | empagliflozin (+/- linagliptin, metformin) <sup>f</sup> |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Biguanide Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Sulfonylureas Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | chlorpropamide <sup>e</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | glimepiride (+/- pioglitazone, rosiglitazone) <sup>e</sup> | tolazamide                                 |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | glipizide (+/- metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | glyburide (+/- metformin)                                  | tolbutamide <sup>e</sup>                   |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Meglitinide Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | nateglinide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | repaglinide (+/- metformin)                                |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Alpha- Glucosidase Inhibitors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | acarbose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | miglitol                                                   |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Thiazolidinedione Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | pioglitazone (+/- alogliptin, glimepiride, metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | rosiglitazone (+/- glimepiride <sup>e</sup> , metformin)   |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | GIP/GLP-1 Receptor Agonist Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | albiglutide <sup>e</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | liraglutide (+/- insulin degludec)                         | semaglutide                                |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | dulaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | lixisenatide (+/- insulin glargine)                        | tirzepatide                                |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | exenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Amylin Analogs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | pramlintide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | DPP-4 Inhibitor Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | alogliptin (+/- metformin, pioglitazone)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | saxagliptin (+/-dapagliflozin, metformin)                  | sitagliptin (+/- metformin, ertugliflozin) |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | linagliptin (+/- empagliflozin, metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Insulin Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| insulin aspart (+/- insulin aspart protamine, niacinamide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | insulin glargine (+/- lixisenatide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | insulin isophane (+/- regular insulin)                     |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| insulin degludec (+/- liraglutide)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | ininsulin glulisine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | insulin lispro (+/- insulin lispro protamine)              |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| insulin detemir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | insulin regular (including inhalation powder)              |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| SGLT2 Inhibitor Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| bexagliflozin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | dapagliflozin (+/- metformin, saxagliptin) <sup>f</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ertugliflozin (+/- sitagliptin, metformin)                 |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| canagliflozin (+/- metformin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | empagliflozin (+/- linagliptin, metformin) <sup>f</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| <p><sup>a</sup> Active ingredients are limited to oral, inhalation and injectable formulations only.</p> <p><sup>b</sup> Excludes nutritional supplement/dietary management combination products, and specific products FDA indicated for weight loss.</p> <p><sup>c</sup> Combination products including dapagliflozin or empagliflozin (and another diabetes medication from the table) are included.</p> <p><sup>d</sup> For biologic reference product contained in the medication table, biosimilar associated with the reference product, regardless of interchangeable status, are also included in the associated value sets, unless otherwise noted.</p> <p><sup>e</sup> There are no active NDCs for albiglutide, chlorpropamide, glimepiride/rosiglitazone or tolbutamide.</p> <p><sup>f</sup> Dapagliflozin and empagliflozin single ingredient products are not included do to FDA-approved non-diabetes indications.</p> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
| Exclusions:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Table STATINS: Statins <sup>a</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <table><tr><th colspan="3">Statin Medications and Combinations</th></tr><tr><td>atorvastatin (+/- amlodipine, ezetimibe)</td><td>pitavastatin</td><td>rosuvastatin (+/- ezetimibe)</td></tr><tr><td>fluvastatin</td><td>pravastatin</td><td>simvastatin (+/- ezetimibe, niacin)</td></tr><tr><td>lovastatin (+/- niacin)</td><td></td><td></td></tr></table>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                            |                                            | Statin Medications and Combinations    |  |  | atorvastatin (+/- amlodipine, ezetimibe)                                                                                                                                                      | pitavastatin | rosuvastatin (+/- ezetimibe) | fluvastatin                                | pravastatin | simvastatin (+/- ezetimibe, niacin) | lovastatin (+/- niacin)     |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Statin Medications and Combinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | atorvastatin (+/- amlodipine, ezetimibe)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | pitavastatin                                               | rosuvastatin (+/- ezetimibe)               |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | fluvastatin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | pravastatin                                                | simvastatin (+/- ezetimibe, niacin)        |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | lovastatin (+/- niacin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <p><sup>a</sup> The active ingredients are limited to oral formulations only.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Beneficiaries enrolled in hospice.<br>Beneficiaries with ESRD.<br>Beneficiaries with rhabdomyolysis, myositis or myopathy.<br>Beneficiaries with Cirrhosis.<br>Beneficiaries with pre-diabetes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                            |                                            |                                        |  |  |                                                                                                                                                                                               |              |                              |                                            |             |                                     |                             |                                                            |            |                           |                           |                          |                                          |  |  |             |                             |  |                               |  |  |          |          |  |                                                |  |  |                                                       |                                                          |  |                                                         |  |  |                          |                                    |             |             |                                     |             |           |  |  |                |  |  |             |  |  |                                              |  |  |                                          |                                           |                                            |                                            |  |  |                                      |  |  |                                                            |                                     |                                        |                                    |                     |                                               |                 |  |                                               |                                              |  |  |               |                                                         |                                            |                               |                                                         |  |



| Concurrent Use of Opioids and Benzodiazepines (COB) | The percentage of Part D beneficiaries, 18 years or older, with concurrent use of prescription opioids and benzodiazepines during the measurement period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--|--|-----------------|-------------|-------|---------------|---------------|-----------|-------------|-------------|-------------|---------|------------|-------------|----------------|-----------|------------|----------|----------|----------|----------------------------|--|--|------------|----------|----------|------------------|-----------|----------|----------|------------|-----------|------------|-----------|-----------|-------------|-----------|--|
| Star Weight:                                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| Provider Action:                                    | <p>Measure population (denominator): Patients 18 years and older who meet BOTH of the following criteria during the measurement year:</p> <ul style="list-style-type: none"><li>• 2 or more opioid prescriptions filled on different dates of service</li><li>• Received cumulative supply of opioids for 15 days or more</li></ul> <p>Measure compliance (numerator): Patients on opioid medication with BOTH of the following criteria during the measurement year:</p> <ul style="list-style-type: none"><li>• Two or more benzodiazepine prescriptions filled with different dates of service</li><li>• Concurrent use of opioids and benzodiazepines for 30 cumulative days or more</li></ul> <p><b>NOTE: A lower rate indicates better performance.</b></p> <p><b>Table COB-A: Opioids <sup>a,b</sup></b></p> <table><tr><th colspan="3">Opioids Medications</th></tr><tr><td>benzhydrocodone</td><td>hydrocodone</td><td>opium</td></tr><tr><td>buprenorphine</td><td>hydromorphone</td><td>oxycodone</td></tr><tr><td>butorphanol</td><td>levorphanol</td><td>oxymorphone</td></tr><tr><td>codeine</td><td>meperidine</td><td>pentazocine</td></tr><tr><td>dihydrocodeine</td><td>methadone</td><td>tapentadol</td></tr><tr><td>fentanyl</td><td>morphine</td><td>tramadol</td></tr></table> <p>a Includes combination products and prescription opioid cough medications.<br/>b Excludes the following: injectable formulations; sublingual sufentanil (used in a supervised setting); and single-agent and combination buprenorphine products used to treat opioid use disorder (i.e., buprenorphine sublingual tablets, Probuphine® Implant kit subcutaneous implant, and all buprenorphine/naloxone combination products).</p> <p><b>Table COB-B: Benzodiazepines <sup>a,b</sup></b></p> <table><tr><th colspan="3">Benzodiazepine Medications</th></tr><tr><td>alprazolam</td><td>diazepam</td><td>oxazepam</td></tr><tr><td>chlordiazepoxide</td><td>estazolam</td><td>quazepam</td></tr><tr><td>clobazam</td><td>flurazepam</td><td>temazepam</td></tr><tr><td>clonazepam</td><td>lorazepam</td><td>triazolam</td></tr><tr><td>clorazepate</td><td>midazolam</td><td></td></tr></table> <p>a Includes combination products.<br/>b Excludes injectable formulations.</p> | Opioids Medications |  |  | benzhydrocodone | hydrocodone | opium | buprenorphine | hydromorphone | oxycodone | butorphanol | levorphanol | oxymorphone | codeine | meperidine | pentazocine | dihydrocodeine | methadone | tapentadol | fentanyl | morphine | tramadol | Benzodiazepine Medications |  |  | alprazolam | diazepam | oxazepam | chlordiazepoxide | estazolam | quazepam | clobazam | flurazepam | temazepam | clonazepam | lorazepam | triazolam | clorazepate | midazolam |  |
| Opioids Medications                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| benzhydrocodone                                     | hydrocodone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | opium               |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| buprenorphine                                       | hydromorphone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | oxycodone           |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| butorphanol                                         | levorphanol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | oxymorphone         |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| codeine                                             | meperidine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | pentazocine         |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| dihydrocodeine                                      | methadone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | tapentadol          |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| fentanyl                                            | morphine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | tramadol            |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| Benzodiazepine Medications                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| alprazolam                                          | diazepam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | oxazepam            |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| chlordiazepoxide                                    | estazolam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | quazepam            |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| clobazam                                            | flurazepam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | temazepam           |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| clonazepam                                          | lorazepam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | triazolam           |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| clorazepate                                         | midazolam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| Reporting:                                          | Captured via pharmacy claims.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |
| Exclusions:                                         | Beneficiaries in Hospice during the measurement year (MY).<br>Beneficiaries with a cancer diagnosis coded during the MY.<br>Beneficiaries with sickle cell disease coded during the MY.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                     |  |  |                 |             |       |               |               |           |             |             |             |         |            |             |                |           |            |          |          |          |                            |  |  |            |          |          |                  |           |          |          |            |           |            |           |           |             |           |  |

|                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--|--|-----------------|-----------------------------|-------------|------------------|------------------------|-----------|----------------|------------|--------------|-------------------------------------------|--|--|-------------|-----------------|--------------|---------------------------------------------|--|--|-----------------|--------------|--|-----------------------------------|--|--|---------------|----------------------------------|--|-----------|------------|--|--------------|---------------|--|-------------|------------|--|----------------------------------|--|--|----------------|------------|--|-----------|--------------|--|-----------------------------------------------------------|--|--|-------------|------------|----------|--------------|-------------|--|-----------|-------------|--|----------------------------------|--|--|--------------------------------|-----------------------------------|--|-----------------------------------------|-------------|--|-------------|-----------------------------------|--|-------------------------------|--|--|------------------|--------------|--|
| Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults (Poly-ACH) | The percentage of Part D beneficiaries 65 years of age or older with concurrent use of two or more unique anticholinergic (ACH) medications during the measurement period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| Star Weight:                                                                         | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| Provider Action:                                                                     | <p>Measure population (denominator): Patients 65 yrs. + with 2 or more prescriptions filled for the same anticholinergic medication on different dates of service during the measurement year.</p> <p>Measure compliance (numerator): Patients with concurrent use of 2 or more unique anticholinergic medications filled for at least a 30-day supply on different dates of service.</p> <p><b>NOTE: A lower rate indicates better performance.</b></p> <p><b>Table POLY-ACH-A: Anticholinergic Medications<sup>a,b</sup></b></p> <table><tr><td colspan="3"><b>Antihistamine Medications</b></td></tr><tr><td>brompheniramine</td><td>Dimenhydrinate <sup>c</sup></td><td>hydroxyzine</td></tr><tr><td>chlorpheniramine</td><td>diphenhydramine (oral)</td><td>meclizine</td></tr><tr><td>cycloheptadine</td><td>doxylamine</td><td>triprolidine</td></tr><tr><td colspan="3"><b>Antiparkinsonian Agent Medications</b></td></tr><tr><td>benztropine</td><td>trihexyphenidyl</td><td>orphenadrine</td></tr><tr><td colspan="3"><b>Skeletal Muscle Relaxant Medications</b></td></tr><tr><td>cyclobenzaprine</td><td>orphenadrine</td><td></td></tr><tr><td colspan="3"><b>Antidepressant Medications</b></td></tr><tr><td>amitriptyline</td><td>doxepin (&gt;6 mg/day)<sup>c</sup></td><td></td></tr><tr><td>amoxapine</td><td>imipramine</td><td></td></tr><tr><td>clomipramine</td><td>nortriptyline</td><td></td></tr><tr><td>desipramine</td><td>paroxetine</td><td></td></tr><tr><td colspan="3"><b>Antipsychotic Medications</b></td></tr><tr><td>chlorpromazine</td><td>olanzapine</td><td></td></tr><tr><td>clozapine</td><td>perphenazine</td><td></td></tr><tr><td colspan="3"><b>Antimuscarinics (urinary incontinence) Medications</b></td></tr><tr><td>darifenacin</td><td>oxybutynin</td><td>trospium</td></tr><tr><td>fesoterodine</td><td>solifenacin</td><td></td></tr><tr><td>flavoxate</td><td>tolterodine</td><td></td></tr><tr><td colspan="3"><b>Antispasmodic Medications</b></td></tr><tr><td>atropine (excludes ophthalmic)</td><td>homatropine (excludes ophthalmic)</td><td></td></tr><tr><td>clidinium-chlordiazepoxide<sup>d</sup></td><td>hyoscyamine</td><td></td></tr><tr><td>dicyclomine</td><td>scopolamine (excludes ophthalmic)</td><td></td></tr><tr><td colspan="3"><b>Antiemetic Medications</b></td></tr><tr><td>prochlorperazine</td><td>promethazine</td><td></td></tr></table> | <b>Antihistamine Medications</b> |  |  | brompheniramine | Dimenhydrinate <sup>c</sup> | hydroxyzine | chlorpheniramine | diphenhydramine (oral) | meclizine | cycloheptadine | doxylamine | triprolidine | <b>Antiparkinsonian Agent Medications</b> |  |  | benztropine | trihexyphenidyl | orphenadrine | <b>Skeletal Muscle Relaxant Medications</b> |  |  | cyclobenzaprine | orphenadrine |  | <b>Antidepressant Medications</b> |  |  | amitriptyline | doxepin (>6 mg/day) <sup>c</sup> |  | amoxapine | imipramine |  | clomipramine | nortriptyline |  | desipramine | paroxetine |  | <b>Antipsychotic Medications</b> |  |  | chlorpromazine | olanzapine |  | clozapine | perphenazine |  | <b>Antimuscarinics (urinary incontinence) Medications</b> |  |  | darifenacin | oxybutynin | trospium | fesoterodine | solifenacin |  | flavoxate | tolterodine |  | <b>Antispasmodic Medications</b> |  |  | atropine (excludes ophthalmic) | homatropine (excludes ophthalmic) |  | clidinium-chlordiazepoxide <sup>d</sup> | hyoscyamine |  | dicyclomine | scopolamine (excludes ophthalmic) |  | <b>Antiemetic Medications</b> |  |  | prochlorperazine | promethazine |  |
| <b>Antihistamine Medications</b>                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| brompheniramine                                                                      | Dimenhydrinate <sup>c</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | hydroxyzine                      |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| chlorpheniramine                                                                     | diphenhydramine (oral)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | meclizine                        |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| cycloheptadine                                                                       | doxylamine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | triprolidine                     |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Antiparkinsonian Agent Medications</b>                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| benztropine                                                                          | trihexyphenidyl                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | orphenadrine                     |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Skeletal Muscle Relaxant Medications</b>                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| cyclobenzaprine                                                                      | orphenadrine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Antidepressant Medications</b>                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| amitriptyline                                                                        | doxepin (>6 mg/day) <sup>c</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| amoxapine                                                                            | imipramine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| clomipramine                                                                         | nortriptyline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| desipramine                                                                          | paroxetine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Antipsychotic Medications</b>                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| chlorpromazine                                                                       | olanzapine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| clozapine                                                                            | perphenazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Antimuscarinics (urinary incontinence) Medications</b>                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| darifenacin                                                                          | oxybutynin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | trospium                         |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| fesoterodine                                                                         | solifenacin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| flavoxate                                                                            | tolterodine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Antispasmodic Medications</b>                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| atropine (excludes ophthalmic)                                                       | homatropine (excludes ophthalmic)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| clidinium-chlordiazepoxide <sup>d</sup>                                              | hyoscyamine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| dicyclomine                                                                          | scopolamine (excludes ophthalmic)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| <b>Antiemetic Medications</b>                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |
| prochlorperazine                                                                     | promethazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                  |  |  |                 |                             |             |                  |                        |           |                |            |              |                                           |  |  |             |                 |              |                                             |  |  |                 |              |  |                                   |  |  |               |                                  |  |           |            |  |              |               |  |             |            |  |                                  |  |  |                |            |  |           |              |  |                                                           |  |  |             |            |          |              |             |  |           |             |  |                                  |  |  |                                |                                   |  |                                         |             |  |             |                                   |  |                               |  |  |                  |              |  |

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                    | <p>a Includes combination products that contain a target medication listed and the following routes of administration: buccal, nasal, oral, transdermal, rectal, and sublingual. Injectable and inhalation routes of administration are not included (not able to accurately estimate days' supply needed for measure logic). For combination products that contain more than one target medication, each target medication (active ingredient) should be considered independently.</p> <p>b Source: Medications in this table are from Table 7 of the American Geriatric Society 2019 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.</p> <p>c There are no active NDCs for dimenhydrinate.</p> <p>d During the individual's measurement year, calculate a daily dose for each fill of doxepin with the following formula: (quantity dispensed x dose)/days' supply; For both denominator and numerator calculation, only include prescription claims for doxepin where the daily dose is &gt;6 mg/day.</p> <p>e Chlordiazepoxide is not a target medication as a single drug.</p> |
| <b>Reporting:</b>  | Captured via pharmacy claims.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusions:</b> | Beneficiaries in Hospice during the measurement year (MY).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Display Measures

### Newly Introduced Measures

Below are newly introduced measures. HEDIS measures are evaluated yearly. Measures may be updated, changed, or recommended for retirement.

### Social Needs Screening and Intervention

|                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Social Need Screening and Intervention (SNS-E)</b> | <b>The percentage of members who were screened, using prespecified instruments, at least once during the measurement period for unmet food, housing and transportation needs, and received a corresponding intervention if they screened positive.</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Star Weight:</b>                                   | Display                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Measure indicators:</b>                            | <ul style="list-style-type: none"> <li>• Food screening: The percentage of members who were screened for unmet food needs.</li> <li>• Food intervention: The percentage of members who received a corresponding intervention within 1 month of screening positive for unmet food needs.</li> <li>• Housing screening: The percentage of members who were screened for unmet housing needs.</li> <li>• Housing intervention: The percentage of members who received a corresponding intervention within 1 month of screening positive for unmet housing needs.</li> <li>• Transportation screening: The percentage of members who were screened for unmet transportation needs.</li> <li>• Transportation intervention: The percentage of members who received a corresponding intervention within 1 month of screening positive for unmet transportation needs.</li> </ul> |
| <b>Provider Action:</b>                               | Screen members for food, housing, and transportation needs using an eligible screening instrument with thresholds for positive findings; provide a corresponding intervention from the following categories when screening is positive: assistance, assessment, counseling, coordination, education, evaluation of eligibility, provision or referral.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Reporting and Coding:</b>                          | Reported from Electronic Clinical Data Systems, e.g. EHR, clinical registry, case management database, admin/enrollment database<br>Per NCQA technical specifications, an extensive list of codes is included in the value set, including CPT, HCPCS, and LOINC codes used to report screening instruments.<br>For codes, please consult NCQA.org.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusions:</b>                                    | Members in Hospice.<br>Members deceased during the measurement period.<br>Members enrolled in an I-SNP any time during the measurement year or living long-term in an institution (LTI).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

## Adult Immunization Status

| Adult Immunization Status (AISE) | The percentage of members 19 years of age and older who are up to date on recommended routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap), zoster, pneumococcal and hepatitis B.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Star Weight:</b>              | Display                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Measure indicators:</b>       | <ul style="list-style-type: none"> <li>Members (aged 19 or older) who received an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period, or members with anaphylaxis due to the influenza vaccine any time before or during the measurement period.</li> <li>Members (aged 19 or older) who received at least one Td vaccine or one Tdap vaccine between 9 years prior to the start of the measurement period, or members with a history of at least one of the following contraindications any time before or during the measurement period: <ul style="list-style-type: none"> <li>Anaphylaxis due to the diphtheria, tetanus or pertussis vaccine.</li> <li>Encephalitis due to the diphtheria, tetanus or pertussis vaccine.</li> </ul> </li> <li>Members (aged 50 and older) who received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine at least 28 days apart, any time on or after the member's 50th birthday and before or during the measurement period, or Members with anaphylaxis due to the herpes zoster vaccine any time before or during the measurement period..</li> <li>Members (aged 65 and older) who were administered at least one dose of an adult pneumococcal vaccine on or after their 19th birthday and before or during the measurement period, or members with anaphylaxis due to the pneumococcal vaccine any time before or during the measurement period.</li> <li>Members (19-59 years) who received at least three doses of the childhood hepatitis B vaccine with different dates of service on or before their 19th birthday; members who received a hepatitis B vaccine series on or after their 19th birthday, before or during the measurement period; members who had a hepatitis B surface antigen, hepatitis B surface antibody or total antibody to hepatitis B core antigen test, with a positive result any time before or during the measurement period; members with a history of hepatitis B illness before or during the measurement period; Members with anaphylaxis due to the hepatitis B vaccine any time before or during the measurement period.</li> </ul> |
| <b>Provider Action:</b>          | Use correct codes to capture vaccines given or identify anaphylaxis code to reflect contraindications.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coding*:</b>                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>CPT 4</b>                     | Adult Influenza Vaccine Procedure: 90630, 90653-90654, 90656, 90658, 90660-90662, 90672-90674, 90682, 90686, 90688-90689, 90694, 90756<br>Td Vaccine Procedure: 90714<br>Tdap Vaccine Procedure: 90715<br>Varicella Zoster (VZV) Vaccine Procedure: 90736, 90750<br>Adult Pneumococcal Vaccine Procedure: 90670-90671, 90677, 90732                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusions:</b>               | Members in Hospice.<br>Members deceased during the measurement period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| * Codes are subject to change.   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Depression Screening and Follow-Up

| Depression Screening and Follow-Up (DSF-E) | The percentage of members who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Star Weight:</b>                        | Display                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Measure indicators:</b>                 | <ul style="list-style-type: none"> <li>Depression Screening. The percentage of members who were screened for clinical depression using a standardized instrument.</li> <li>Follow-Up on Positive Screen. The percentage of members who received follow-up care within 30 days of a positive depression screen finding.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Provider Action:</b>                    | Screen members for depression using an age appropriate, standardized screening instrument; provide follow-up care on or up to 30 days after the date of the first positive screen (31 total days). Any of the following on or up to 30 days after the first positive screen: <ul style="list-style-type: none"> <li>An outpatient, telephone, e-visit or virtual check-in follow-up visit with a diagnosis of depression or other behavioral health condition.</li> <li>A depression case management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.</li> <li>A behavioral health encounter, including assessment, therapy, collaborative care or medication management.</li> <li>A dispensed antidepressant medication.</li> <li>Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow-up (i.e., a negative screen) on the same day as a positive screen on a brief screening instrument.</li> </ul> |
| <b>Reporting and Coding:</b>               | Reported from Electronic Clinical Data Systems, e.g. EHR, clinical registry, case management database, admin/enrollment database.<br>Per NCQA HEDIS Specifications there are over 1,200 codes for this value set. For codes, please consult NCQA.org.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusions:</b>                         | Members in Hospice.<br>Members deceased during the measurement period.<br>Members with a history of bipolar disorder any time during the member's history through the end of the year prior to the measurement period.<br>Members with depression that starts during the year prior to the measurement period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Advanced Illness and Frailty

Patients with an advanced illness diagnosis or limited life expectancy may not benefit from recommended services required to meet certain quality measures. Unnecessary tests and treatments may be burdensome or even harmful to these patients. To account for this the National Committee for Quality Assurance (NCQA) has included exclusions for advanced illness and frailty in their technical specifications.

### **To qualify, patients must have at least one of the following in the measurement year or year prior:**

- Two outpatient claims on different dates of service with an advanced illness code OR
- One inpatient claim with an advanced illness code OR
- One filled prescription for a dementia medication

### **AND**

- At least two indications of frailty (diagnosis or treatment claims) with different dates of service during the measurement year.

### **Exclusions can be applied to the following HEDIS Star Measures:**

|                                                  |                                                 |
|--------------------------------------------------|-------------------------------------------------|
| Breast Cancer Screening (BCS-E)                  | Osteoporosis Management in Women with a         |
| Colorectal Cancer Screening (COL-E)              | Fracture (OMW)*                                 |
| Care for Patients with Diabetes (GSD, EED, KED*) | Statin Therapy for Patients with Cardiovascular |
| Controlling Blood Pressure (CBP)*                | Disease (SPC)                                   |

\*Patients age 81 and older can be excluded with a frailty diagnosis or treatment alone.

For a complete listing of advanced illness and frailty codes please visit [NCQA.org](http://NCQA.org) or contact us at [StarsAndHEDIS@mchs.com](mailto:StarsAndHEDIS@mchs.com).

## Contact Us

Please send us an email at:  
[StarsAndHEDIS@mchs.com](mailto:StarsAndHEDIS@mchs.com).

If you would like to receive gaps in care information specific to your patients, email us and provide the following:

1. **Practice name.**
2. **All associated primary care providers (PCPs).**
3. **Contact name.**
4. **Contact phone number.**



